Chester County News and Community Website
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) will present updates on its experimental Alzheimer’s disease treatment buntanetap at a November medical conference in Boston as the Malvern-based biotechnology company …
Annovis Targets 2027 Alzheimer’s Drug Data Readout Read More
WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) has received clearance from the U.S. Food and Drug Administration to resume clinical development of its experimental hepatitis B treatment AB-101 in …
Arbutus Wins FDA Clearance to Resume Hepatitis B Drug Trials Read More
NEWTOWN SQUARE, PA — ArriVent BioPharma Inc. (Nasdaq: AVBP) reported a 68% tumor response rate and median progression-free survival of 16 months at the higher dose of its experimental lung …
ArriVent Lung Cancer Drug Shows 68% Response Rate in Trial Read More
PHILADELPHIA, PA — Virion Therapeutics will present long-term clinical trial results for its experimental hepatitis B immunotherapy, VRON-0200, on November 9 at a major liver disease conference in Denver, providing …
Virion to Present Two-Year Hepatitis B Treatment Data Read More
WAYNE, PA — Teleflex Incorporated (NYSE: TFX) has completed enrollment of 102 patients in a European clinical study evaluating longer versions of its dissolvable magnesium coronary scaffold, advancing research into …
Teleflex Completes Enrollment in Coronary Scaffold Trial Read More
CONSHOHOCKEN, PA — Suvoda is extending its artificial intelligence assistant to all new clinical trials using its RTSM/IRT or eCOA systems, allowing pharmaceutical sponsors, contract research organizations and research sites …
Suvoda Expands AI Automation Across New Clinical Trials Read More
SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) reported new Phase 3 clinical trial results showing sustained remission in patients receiving its Crohn’s disease treatment Tremfya for three years, …
Johnson & Johnson Reports Three-Year Crohn’s Drug Results Read More NEWTOWN SQUARE, PA — ArriVent BioPharma Inc. (Nasdaq: AVBP) has dosed the first patient in a U.S. Phase 1 clinical trial of ARR-002, an experimental antibody-drug conjugate targeting ovarian and …
ArriVent Advances Cancer Drug Pipeline With First U.S. Trial Read More SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) reported that more than 70% of patients receiving its oral psoriasis treatment ICOTYDE maintained clear or almost clear skin through two …
Johnson & Johnson Reports Sustained Psoriasis Drug Response Read More
RADNOR, PA — Mineralys Therapeutics Inc. (Nasdaq: MLYS) reported additional clinical evidence that its experimental hypertension drug lorundrostat can lower blood pressure in patients whose condition remains uncontrolled despite multiple …
Mineralys Drug Lowers Blood Pressure but Misses Sleep Apnea Goal Read More